CompaniesFrame Cancer Therapeutics

Frame Cancer Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

3

As Collaborator

0

Total Enrollment

81

By Phase

PHASE2: 3

By Status

COMPLETED: 3
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
Today
NCT00062257
NCT00077402
NCT00077415
Hover over trial bars to see details

Recent Trials

NCT00077415Lead Sponsor
3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
PHASE2Completed
31 participants
Started: Apr 30, 2004 · Completed: Feb 29, 2008
NCT00077402Lead Sponsor
Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer
PHASE2Completed
50 participants
Started: Nov 30, 2003 · Completed: Feb 28, 2011
NCT00062257Lead Sponsor
Irofulven in Treating Patients With Recurrent or Metastatic Gastric Cancer
PHASE2Completed
Started: Jun 30, 2003 · Completed: Sep 30, 2006
Related Companies
Curevac
acquired